Erythropoiesis-Stimulating Agents in Anemia: Use and Misuse

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Erythropoiesis-stimulating agents (ESAs) have been in use for 2 decades. After the initial introduction for their use in anemia of end-stage renal disease, indications for the use of ESAs have widened to anemia of predialysis chronic kidney disease, cancer chemotherapy, HIV disease and orthopedic surgery. Along with the considerable benefits associated with the use of ESAs, adverse events have become apparent, in large part from overcorrection of the anemia. Data from recent studies have prompted several FDA warnings imposing the health provider to follow stringent criteria for the use of ESAs; these include close follow-up of patients, along with use of specific laboratory tests and criteria for dosing. Although adverse effects may partly relate to misuse, when appropriately administered, ESAs are useful agents in the medication armamentarium in the treatment of certain forms of anemia, with potential to improve outcomes and quality of life in some anemic individuals.

Original languageEnglish (US)
Pages (from-to)607-616
Number of pages10
JournalJournal of the American Medical Directors Association
Volume10
Issue number9
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Hematinics
Anemia
Kidney Neoplasms
Chronic Renal Insufficiency
Chronic Kidney Failure
Orthopedics
Quality of Life
HIV
Drug Therapy
Health

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Health Policy

Cite this

Erythropoiesis-Stimulating Agents in Anemia : Use and Misuse. / Dharmarajan, Thiruvinvamalai S.; Widjaja, David.

In: Journal of the American Medical Directors Association, Vol. 10, No. 9, 11.2009, p. 607-616.

Research output: Contribution to journalArticle

@article{18d2971f19e448b793c16d397233f36e,
title = "Erythropoiesis-Stimulating Agents in Anemia: Use and Misuse",
abstract = "Erythropoiesis-stimulating agents (ESAs) have been in use for 2 decades. After the initial introduction for their use in anemia of end-stage renal disease, indications for the use of ESAs have widened to anemia of predialysis chronic kidney disease, cancer chemotherapy, HIV disease and orthopedic surgery. Along with the considerable benefits associated with the use of ESAs, adverse events have become apparent, in large part from overcorrection of the anemia. Data from recent studies have prompted several FDA warnings imposing the health provider to follow stringent criteria for the use of ESAs; these include close follow-up of patients, along with use of specific laboratory tests and criteria for dosing. Although adverse effects may partly relate to misuse, when appropriately administered, ESAs are useful agents in the medication armamentarium in the treatment of certain forms of anemia, with potential to improve outcomes and quality of life in some anemic individuals.",
author = "Dharmarajan, {Thiruvinvamalai S.} and David Widjaja",
year = "2009",
month = "11",
doi = "10.1016/j.jamda.2009.05.003",
language = "English (US)",
volume = "10",
pages = "607--616",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Erythropoiesis-Stimulating Agents in Anemia

T2 - Use and Misuse

AU - Dharmarajan, Thiruvinvamalai S.

AU - Widjaja, David

PY - 2009/11

Y1 - 2009/11

N2 - Erythropoiesis-stimulating agents (ESAs) have been in use for 2 decades. After the initial introduction for their use in anemia of end-stage renal disease, indications for the use of ESAs have widened to anemia of predialysis chronic kidney disease, cancer chemotherapy, HIV disease and orthopedic surgery. Along with the considerable benefits associated with the use of ESAs, adverse events have become apparent, in large part from overcorrection of the anemia. Data from recent studies have prompted several FDA warnings imposing the health provider to follow stringent criteria for the use of ESAs; these include close follow-up of patients, along with use of specific laboratory tests and criteria for dosing. Although adverse effects may partly relate to misuse, when appropriately administered, ESAs are useful agents in the medication armamentarium in the treatment of certain forms of anemia, with potential to improve outcomes and quality of life in some anemic individuals.

AB - Erythropoiesis-stimulating agents (ESAs) have been in use for 2 decades. After the initial introduction for their use in anemia of end-stage renal disease, indications for the use of ESAs have widened to anemia of predialysis chronic kidney disease, cancer chemotherapy, HIV disease and orthopedic surgery. Along with the considerable benefits associated with the use of ESAs, adverse events have become apparent, in large part from overcorrection of the anemia. Data from recent studies have prompted several FDA warnings imposing the health provider to follow stringent criteria for the use of ESAs; these include close follow-up of patients, along with use of specific laboratory tests and criteria for dosing. Although adverse effects may partly relate to misuse, when appropriately administered, ESAs are useful agents in the medication armamentarium in the treatment of certain forms of anemia, with potential to improve outcomes and quality of life in some anemic individuals.

UR - http://www.scopus.com/inward/record.url?scp=70350356856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350356856&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2009.05.003

DO - 10.1016/j.jamda.2009.05.003

M3 - Article

C2 - 19883882

AN - SCOPUS:70350356856

VL - 10

SP - 607

EP - 616

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 9

ER -